Immunotherapy plus chemo before surgery for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 65.
- You have been diagnosed with triple-negative breast cancer that has not spread to other parts of the body.
- Your tumor is either large (T3 or T4) or has spread to nearby lymph nodes (N+).
- You have not received any previous treatment for this breast cancer.
- You are able to undergo surgery to remove the tumor.
- Your overall health is good (ECOG score 0 or 1) and your major organs are functioning well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether giving the immunotherapy drug camrelizumab along with chemotherapy and radiation before surgery can help shrink early-stage triple-negative breast cancer tumors. It aims to improve treatment outcomes for this aggressive but curable cancer.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.